Floatz logo

EN-3356

Cancer of the Prostate

Asana BioSciencesSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Cancer of the Prostate cohort.

Asset / SponsorPhaseRating
Mevrometostat
Pfizer
Phase 3B
i-131-1095
Progenics Pharmaceuticals, Inc.
Phase 2B
17-beta-estradiol
BHR Pharma, LLC
Phase 2CCC
Bhr-200
BHR Pharma, LLC
Phase 2CCC
RETASPIMYCIN
Infinity Pharmaceuticals, Inc.
Phase 2CCC

View all 9 →

Same molecule, other indications

EN-3356 is also rated in:

Neoplasms, ProstateDormant
CC
Indicative ·
43 / 100
View asset →
Neoplasms, ProstaticDormant
CC
Indicative ·
43 / 100
View asset →
Prostate Neoplasms, Castration-resistantDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →